A Study to Evaluate the Efficacy and Safety of CS32582 in Participants With Moderate to Severe Plaque Psoriasis

" This study consists of two parts: Part 1 (Dose Escalation): A randomized, double-blind, placebo-controlled phase in which approximately 20 to 30 adult patients with plaque psoriasis will receive the investigational treatment for 4 weeks. Part 2 (Efficacy and Safety Assessment): A randomized, double-blind, placebo-controlled evaluation where approximately 200 adult patients with plaque psoriasis will undergo 12 weeks of treatment. The resulting data will provide preliminary evidence on the safety and efficacy profile of CS32582, informing its subsequent development strategy.

NCT Number	NCT07129382
Lead Sponsor	Chipscreen Biosciences, Ltd.
Conditions	Plaque Psoriasis
Enrollment	220 participants
Start Date	2025-09-08
Primary Completion	2027-09-18 (estimated)
Study Completion	2027-09-18 (estimated)
Updated on ClinicalTrials.gov	2025-09-10